After Reaching Milestone, Is Acer Therapeutics Inc (NASDAQ:ACER)’s Short Interest Revealing Something?

The stock of Acer Therapeutics Inc (NASDAQ:ACER) registered an increase of 8.81% in short interest. ACER’s total short interest was 146,900 shares in July as published by FINRA. Its up 8.81% from 135,000 shares, reported previously. With 27,100 shares average volume, it will take short sellers 5 days to cover their ACER’s short positions.

The stock decreased 1.16% or $0.04 during the last trading session, reaching $3.4. About 155,857 shares traded. Acer Therapeutics Inc. (NASDAQ:ACER) has risen 22.47% since July 14, 2018 and is uptrending. It has outperformed by 18.04% the S&P500.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company has market cap of $34.30 million. The firm offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease . It currently has negative earnings. It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD).

Acer Therapeutics Inc. (NASDAQ:ACER) Ratings Coverage

Among 2 analysts covering Acer Therapeutics (NASDAQ:ACER), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Acer Therapeutics has $4800 highest and $40 lowest target. $44’s average target is 1194.12% above currents $3.4 stock price. Acer Therapeutics had 6 analyst reports since February 15, 2019 according to SRatingsIntel. Raymond James maintained it with “Outperform” rating and $40 target in Friday, February 15 report.

More notable recent Acer Therapeutics Inc. (NASDAQ:ACER) news were published by: Finance.Yahoo.com which released: “SHAREHOLDER ALERT – Acer Therapeutics Inc. (ACER) – Bronstein, Gewirtz & Grossman, LLC Notifies of Class Action and Lead Deadline: August 30, 2019 – Yahoo Finance” on July 12, 2019, also Benzinga.com with their article: “The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart – Benzinga” published on June 26, 2019, Nasdaq.com published: “U.S. STOCKS ON THE MOVE-Oasmia, Karyopharm, Electronic Arts – Nasdaq” on July 05, 2019. More interesting news about Acer Therapeutics Inc. (NASDAQ:ACER) were released by: Finance.Yahoo.com and their article: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs – Yahoo Finance” published on June 22, 2019 as well as Globenewswire.com‘s news article titled: “INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for the Southern District of New York against Acer Therapeutics Inc. – GlobeNewswire” with publication date: July 03, 2019.

Acer Therapeutics Inc. (NASDAQ:ACER) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.